Analysis of Serum Vitamin D and Major Histocompatibility Complex Class I-Related Chain a (Mica) Levels in Patients With Breast Carcinoma

Abstract

Introduction: Breast carcinoma is the most deadly cancer in women worldwide, with an incidence rateof 26 cases per 100,000 women in Indonesia. Treatment and prognosis is very dependent on the stage ofbreast carcinoma. Vitamin D can inhibit proliferation and invasive cancer cells, induction of differentiation,apoptosis and promotion of angiogenesis. Major Histocompatibility Complex class I - related chain A(MICA) plays a role in reducing the expression of NKG2D receptors in breast carcinomas so that they canbe targeted for treatment of breast carcinoma treatment. The aim of this study was to determine vitamin Dand MICA levels in serum patients with non-metastatic and metastatic breast carcinoma.Method: We examined 86 samples of breast carcinoma patients (44 non-metastatic samples and 42metastatic samples) with a range of 29 - 68 years old. Vitamin D levels were examined by the EnzymeLinked Flourescent Assay (ELFA) method while the MICA levels were examined by Enzyme LinkedImmunoabsorbant Assay (ELISA).Result: There were significant differences in mean vitamin D levels in non-metastatic and metastatic breastcarcinomas (29.88 ng/mlvs19.06 ng/ml; p <0.01).Serum MICA levels in patients with non-metastatic breastcarcinoma were lower (333.52 pg/ml) than in metastatic breast carcinoma(333.52 pg/mlvs528.71 pg/ml; p<0.01).A negative correlation was found between vitamin D levels andMICA in both groups (Pearson correlation, p: -0.58).Conclusion: Metastatic breast carcinoma had lower vitamin D levels and higher serum MICA levels thannon-metastatic breast carcinoma.